Cargando…
Sustainable rare diseases business and drug access: no time for misconceptions
Legislative incentives enacted in Europe through the Regulation (EC) No. 141/2000 to incentivize orphan drug development have over the last 12 years constituted a powerful impetus toward R&D directed at the rare diseases population. However, despite therapeutic promises contained in these projec...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735431/ https://www.ncbi.nlm.nih.gov/pubmed/23879976 http://dx.doi.org/10.1186/1750-1172-8-109 |